Evommune ratios data for the quarter ended Jun 2026. These financial ratios cover 8 quarters of results from Sep 2024 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Ratios | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||
| EBT Margin | -481.07% | -124.75% | ||||||
| EBIT Margin | -501.07% | -133.28% | ||||||
| EBITDA Margin | -501.07% | -133.28% | ||||||
| Operating Margin | -501.07% | -133.28% | ||||||
| Net Margin | -481.07% | -124.75% | ||||||
| FCF Margin | -796.63% | -97.66% | ||||||
| Efficiency | ||||||||
| Assets AverageAssets Avg. | 154.75M | 273.70M | 312.20M | |||||
| Asset Utilization RatioAsset Util. | 0.08 | 0.04 | 0.03 | |||||
| Leverage & Solvency | ||||||||
| Interest Coverage RatioInterest Cover | -971.59 | 0.02M | -0.00M | -851.63 | -0.00M | -0.01M | -0.02M | |
| Times Interest Earned | -971.59 | 0.02M | -0.00M | -851.63 | -0.00M | -0.01M | -0.02M | |
| Valuation | ||||||||
| Price to EarningsP/E | -3.72 | -38.21 | -14.95 | |||||
| Price to BookP/B | 0.51 | 2.72 | 1.74 | |||||
| Enterprise Value | -44.14M | 616.60M | 281.39M | |||||
| EV to EBIT | 1.49 | -25.74 | -8.06 | |||||
| EV to EBITDA | 1.49 | -25.74 | -8.06 | |||||
| Market Capitalization | 105.06M | 828.06M | 482.18M | |||||
| Price to FCFP/FCF | -6.25 | -30.02 | -23.52 | |||||
| EV to FCF | 2.63 | -22.35 | -13.73 | |||||
| EV to CFO | 2.64 | -22.42 | -13.85 | |||||
| Return Ratios | ||||||||
| Return on Sales [ROS]ROS | -501.07% | -133.28% | -623.62% | -899.92% | -1,018.93% | |||
| Return on Capital Employed [ROCE]ROCE | -59.25% | -34.20% | -34.57% | |||||
| Return on Assets [ROA]ROA | -50.27% | -31.07% | -30.32% |